TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Somnomed Limited ( (AU:SOM) ) has issued an update.
Somnomed Limited has announced a change in the director’s interest, with Andrew Price acquiring 300,000 options. This change, approved at the Annual General Meeting, reflects the company’s ongoing governance and strategic alignment, potentially impacting its operational focus and stakeholder interests.
The most recent analyst rating on (AU:SOM) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
More about Somnomed Limited
Somnomed Limited operates in the healthcare industry, focusing on providing innovative sleep solutions. The company is known for its oral appliance therapy products designed to treat obstructive sleep apnea, catering to a global market.
Average Trading Volume: 373,921
Technical Sentiment Signal: Buy
Current Market Cap: A$176.7M
For an in-depth examination of SOM stock, go to TipRanks’ Overview page.